Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis

  title={Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis},
  author={Jeremy A. Miles and Balaram Krishna Hanumanthu and Kavisha Patel and Michelle Chen and Robert M. Siegel and Damianos G. Kokkinidis},
  journal={Journal of Cardiovascular Medicine},
Aims Loop diuretics have become a mainstay of chronic heart failure management. Furosemide and torsemide are the two most common loop diuretics; nevertheless, there is inconsistent evidence regarding the optimal choice of loop diuretic with respect to clinical outcomes. Methods Medline and Cochrane Databases were systemically reviewed for randomized and observational studies comparing patients with chronic heart failure on oral torsemide versus oral furosemide and their association with… 

Figures from this paper

There is enough convincing evidence to speak about the advantages of torasemide over furosemide both in terms of its pharmacological properties and taking into account the reduction of hospitalizations, functional progress and improvement in the quality of life of patients with heart failure.
An evaluation of torsemide in patients with heart failure and renal disease
The limited current body of evidence indicates that torsemide may be superior to furosemide with respect to improving HF functional status and reducing HF hospitalization, and there are mixed data regarding effect on reducing overall cardiovascular hospitalizations/mortality.
Efficacy of oral torasemide in dogs with degenerative mitral valve disease and new onset congestive heart failure: The CARPODIEM study
Torasemide was noninferior to furosemide as first line PO treatment for new onset CHF caused by DMVD and significantly decreased risk of cardiac‐related death or premature study withdrawal for cardiac reasons compared to f Kurosemide.
Current Clinical and Pharmacological Approaches to the Prescription of Loop Diuretics in Patients with Chronic Heart Failure
Heart failure (HF) is a growing public health problem with an estimated prevalence of 38 million patients worldwide. Congestion and formation of edema – are typical symptoms of heart failure.
Impact of Loop Diuretic on Outcomes in Patients with Heart Failure and Reduced Ejection Fraction
Loop diuretic use is recommended in order to alleviate symptoms, improve exercise capacity, and reduce hospitalizations in patients with heart failure and their use should be limited to the lowest dose necessary to maintain euvolemia.
Results of several studies state that torasemide helps in improving the left ventricular function, reduces the mortality, as well as the frequency and duration of heart failure, and improves the quality of life, tolerance and NYHA functional class in patients suffering from CHF.
Diuretic Resistance in Heart Failure.
The therapeutic approach to this common problem typically involves increases in the diuretic dose and/or frequency, sequential nephron blockade, and mechanical fluid movement removal with ultrafiltration or peritoneal dialysis.
Home Therapies in Advanced Heart Failure: Inotropes and Diuretics
Ambulatory use of diuretics and inotropes may improve patients’ QOL through symptom management and reduced hospitalizations, however, risks and limitations of both modalities must be considered as treatment decisions are made.
New perspectives and future directions in the treatment of heart failure
The management of heart failure has changed significantly over the last 30 years, leading to improvements in the quality of life and outcomes, at least for patients with a substantially reduced left
Furosemide Diuretic Activity Evaluation in Female Sprague-Dawley Rats
The rapid onset of action and brief effect showed by Furosemide is consistent with what is established in the literature and the slight decrease in post-treatment urinary pH with respect to the basal level, adjusts to the effect of FuroSemide itself and to the expansion effect of the urinary volume.


Should torsemide be the loop diuretic of choice in systolic heart failure?
Compared with furosemide, torsemide significantly reduces HF and CV-related hospital readmissions in systolic HF and is associated with a trend in reducing all-cause mortality.
Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial.
Patients treated with torsemide had features of greater disease severity, similar 30-day outcomes but increased 150-day mortality, and Prospective randomized trials are needed to investigate the effect of Torsemide versus furosemide.
Torsemide Versus Furosemide in Heart Failure Patients: Insights From Duke University Hospital
Furosemide has historically been the primary loop diuretic in heart failure patients despite data suggesting potential advantages with torsemide, and the relationship with all-cause mortality through 5 years was assessed.
Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint.
Treating patients suffering from congestive heart failure with torasemide improved clinical outcome and was more cost-effective than with furosemide, according to a cost-effectiveness analysis.
Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods.
Chronic diuretic use was associated with increased long-term mortality and hospitalizations in a wide spectrum of ambulatory chronic systolic and diastolic HF patients, challenging the wisdom of routine chronic use of diuretics in HF patients who are asymptomatic or minimally symptomatic without fluid retention.